我司的优势 1)团队具备多年500强美资企业的法规工作经验; 2)具有成功国内的近百家企业通过FDA审核的经验; 3)具有成功FDA提前五天通知的飞行检查的经验; 咨询师具有的语言能力,担任陪审和翻译的任务会使得企业应对更轻松。
![FDA代理人](http://static.11467.com/img/lazy.gif)
QSR820审核的可能的结果 NAI(审核无483直接通过) VAI(审核有483,是一般不符合) OAI(审核有483,是严重不符合) Warning Letter 警告信(企业必须在规定期限回复,有可能需要再次审核进行验证) Import Alert 进口禁令(企业产品到美国海关会被自动扣留,进入DWPE程序)
![FDA代理人](http://static.11467.com/img/lazy.gif)
FDA 化妆品注册怎么做? FDA化妆品成分申报 《联邦食品、药品和化妆品法案》(FFDCA)是这样定义”标签”的,所有的标签和其他以书写、印刷和绘制方式随附在药品本身、容器或外包装上的内容,包括包装盒内的资料。术语“随附”并不只限于产品本身,它可延伸到产品的海报、标牌、手册、、广告小册子、宣传册、指南和网页等。 美国对化妆品的成分和标签有严格的法律规定,而且有的化妆品在美国实际上是被划分为药品进行监管的。SUNGO的标签和成分审核服务将通过对美国《联邦法典》、《联邦公报》、VCRP化妆品成分词典、指南性文件、美国FDA标签手册(U.S. FDA Labeling Manual)、警告信等繁杂法规资料的检索和对照,协助企业全方面遵守美国FDA化妆品法规,SUNGO提供以下化妆品标签审核服务: · 一份由我们法规团队对您标签中每一个元素(包括内包装、外包装、网站,等等)审核后准备的详细报告(一般为30-40页)。 · 一份已经修改完成的可以直接印刷的电子图稿。 · 如果同一标签在45天内有变化,我们将免费提供另外的报告和审核修改。 · 如产品销往加州,协助企业完成《加利福尼亚州化妆品安全计划》报告,《加利福尼亚州化妆品安全计划》要求生产商、包装商、经销商确认并列出化妆品标签所有含有已被确定或怀疑会导致、畸形、发育不良或生殖毒性成分的化妆品(包括色素和香料产品)必须向加州政府呈交报告。
![FDA代理人](http://static.11467.com/img/lazy.gif)
Responsibilities of a U.S. agent The U.S. agent must either reside in the U.S. or maintain a place of business in the U.S. The U.S. agent cannot use a post office box as an address. The U.S. agent cannot use an answering service. They must be available to answer the phone or have an employee available to answer the phone during normal business hours. The responsibilities of the U.S. agent are limited and include: assisting FDA in communications with the foreign establishment, responding to concerning the foreign establishment's devices that are imported or offered for import into the United States, assisting FDA in scheduling inspections of the foreign establishment and if FDA is unable to contact the foreign establishment directly or expeditiously, FDA may provide information or documents to the U.S. agent, and such an action shall be considered to be e to providing the same information or documents to the foreign establishment. Please note that the U.S. agent has no responsibility related to reporting of adverse events under the Medical Device Reporting regulation (21 CFR Part 803), or submitting 510(k) Premarket Notifications (21 CFR Part 807, Subpart E).